In Brief
Refine Search
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Biosimilars
Yesterday, the US Food and Drug Administration (FDA) issued a draft guidance, Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products. 23 July 2024
Pharmaceutical
Innovent Biologics (HKEX: 01801) has announced positive results from the Phase III DREAMS-1 trial of mazdutide. 23 July 2024
Biotechnology
California-based liver and viral disease specialist Aligos Therapeutics (Nasdaq: ALGS) has announced a clinical trial collaboration with Amoytop Biotech. 23 July 2024
Biotechnology
Agilent Technologies has signed a definitive agreement to acquire Biovectra, a leading specialized contract development and manufacturing organization (CDMO), for $925 million. 23 July 2024
Pharmaceutical
Chugai today announced it will transfer to Maruishi Pharmaceuticals the business in Japan concerning the physiological intestinal function improving and hyperammonemia drug Monilac 22 July 2024
Pharmaceutical
The Organization of Pharmaceutical Producers of India (OPPI) has urged the government to exempt patented and orphan drugs from price control. 22 July 2024
Pharmaceutical
Spanish dermatology specialist Almirall was trading 4% higher at the end of Monday’s trading day in Barcelona. 22 July 2024
Biosimilars
The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) submitted by South Korea’s Samsung Bioepis for Epysqli (eculizumab-aagh) as a biosimilar to Soliris (eculizumab). 22 July 2024
Biotechnology
A new collaboration in the area of stem cell therapies is to get underway in Japan, as Tokyo-based drugmaker Astellas Pharma (TSE: 4503) pairs up with Osaka University. 22 July 2024
Biotechnology
San Diego-based Artiva Biotherapeutics (Nasdaq: ARTV) has announced the pricing of an upsized $167 million initial public offering (IPO). 22 July 2024
article
STADA Arzneimittel and Iceland-based Alvotech have launched Uzpruvo, the first approved biosimilar to Stelara (ustekinumab) in Europe, across a majority of European countries. 22 July 2024
Pharmaceutical
German family-owned pain focused drugmaker Grünenthal has announced the acquisition of USA-based Valinor Pharma. 22 July 2024
Pharmaceutical
Swiss firm Addex Therapeutics (SIX: ADXN) has reported that its partner Johnson & Johnson (NYSE: JNJ) has halted the development of ADX71149 for epilepsy. 22 July 2024
Biotechnology
A recent draft report from the Institute for Clinical and Economic Review (ICER) has evaluated the cost-effectiveness of therapies for transthyretin amyloid cardiomyopathy (ATTR-CM), warning that in some cases, the price is too high. 22 July 2024
Biotechnology
Destiny Pharma saw its shares fall almost 15% to 4.00 pence this morning, despite announcing positive trial results. 22 July 2024
Biotechnology
GRO Biosciences on Friday announced the closing of an oversubscribed $60.3 million Series B financing. 22 July 2024
Biotechnology
Shanghai, China-based Rona Therapeutics on Friday announced the completion of $35 million Series A+ financing. 22 July 2024
Pharmaceutical
Last week, US healthcare giant Johnson & Johnson kicked off the second-quarter financial reporting period, posting better than expected results and raising its full-year forecast. The USA’s Biomedical Advanced Research and Development Authority (BARDA) recently announced that it has committed up to $500 million to fund next generation COVID vaccines. US biotech Caribou Biosciences said it is refocusing its research and cutting back its workforce. Also of note, Roche subsidiary Genentech terminated its collaboration with US precision medicines company Relay Therapeutics on migoprotafib. 21 July 2024
Generics
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Friday approved the first generic raltegravir medicines to treat adult and pediatric HIV patients 20 July 2024
Pharmaceutical
Meitheal Pharmaceuticals has acquired North America rights to Contempo (fosfomycin for injection) from Nabriva Therapeutics. 20 July 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze